cell therapy

A magnified view of a CD34+ stem cell

AI system developed to determine optimal conditions for regenerative medicine

A robotic AI system has been developed by scientists that is capable of improving stem cell culture procedures that are utilized in regenerative medicine. 

Cell therapy co. Gamida Cell announces USD 75 m. financing

Gamida Cell is a cell therapy company working to develop and commercialize cures for blood cancers and blood diseases.

Pluristem to terminate Phase III study of critical limb ischemia (CLI)

While the CLI study was unsuccessful, Yanay said the company is maintaining a forward-thinking attitude, looking toward the development of other treatments it has in the works.

Prof. Boaz Lerner of Ben-Gurion University uses a new platform for predicting ALS disease progressio

Investigational drug proven to prolong survival of ALS patients - study

The median overall survival for all CENTAUR study participants being administered AMX0035 was 6.5 months longer than the group originally randomized to placebo.

Immunai co-founders (from left) Luis Voloch and Noam Solomon

Israel’s Immunai first to map whole immune system, scores $20m. investment

Immunai says it has mapped out millions of immune cells and their functions that could help detect, diagnose and treat cancer and many other diseases.

Israeli cell therapy company offers solution after failed Russian experiment

Radiation poisoning, known in the medical world as acute radiation syndrome or ARS, is a grave illness that often leads to death.

Pluristem gets positive results from radiation treatment trials

“We believe that this outcome is an important contribution to protect the armed and medical forces which may need to enter contaminated areas,” Chief Executive Officer Yaky Yanay said.

Ben-Gurion University of the Negev.

BGU researchers discover sense of ‘touch’ in blood cells

Lymphocytes found to differentiate healthy cells from sick ones through chemical and mechanical reactions

A Pluristem scientist in the process of making its cell products and a look at the final product its

USFDA clears Plursitem for expanded access program

Patients suffering from critical limb ischemia can now benefit without being part of clinical trials

Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy